Ivonescimab with chemoradiation for high-risk nasopharyngeal cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial tests adding ivonescimab, an immunotherapy drug, to standard chemoradiation for a type of nasopharyngeal cancer that has a higher risk of coming back. It aims to see if this combination can improve outcomes for patients with stage T3N2 or stage III disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have a type of nasopharyngeal cancer called non-keratinizing carcinoma (confirmed by biopsy).
- You are in good physical condition (able to do daily activities without help).
- Your cancer is at stage T3N2M0 or stage III by AJCC 9th edition and has not been treated before.
- Your blood cell counts, liver and kidney function, and other key lab tests are within acceptable ranges.
- You agree to use reliable birth control if you or your partner could become pregnant, from screening until one year after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ivonescimab in patients whose nasopharyngeal cancer (a type of head and neck cancer) has spread or come back after previous chemotherapy and immunotherapy failed to stop it. The drug works by helping your immune system fight the cancer in a different way.
This trial tests a combination of low-dose radiation and immunotherapy (drugs that help your immune system fight cancer) for people with nasopharyngeal cancer that has spread to other parts of the body and who cannot receive chemotherapy. The goal is to see if this treatment can help control the cancer and improve outcomes.
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
This trial tests two drugs—scipibaimab and tislelizumab—given together for people with nasopharyngeal cancer that has not responded to first-line platinum chemotherapy and a PD-1 inhibitor. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of a new immunotherapy (QL1706) plus standard chemoradiation for people with advanced nasopharyngeal cancer that hasn't spread to distant organs. The goal is to see if adding this drug helps control the cancer better than standard treatment alone.
This trial is testing a combination of drugs for people whose nasopharyngeal cancer has stopped responding to standard treatments like platinum chemotherapy and PD-1 inhibitors. It aims to find a new effective approach for advanced or recurrent disease.
Hear when a new Nasopharyngeal Carcinoma (NPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.